ClinicalTrials.gg
Status unknownNCT05803642Updated Apr 7, 2023

A Study of Olanzapine in Patients With Acute Agitation

A Phase 3 interventional study of Olanzapine and Haloperidol in Acute Agitation, sponsored by Qilu Pharmaceutical Co., Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of intramuscular olanzapine for the treatment of acute agitation associated with schizophrenia and bipolar I mania.

02

Conditions studied

  • Acute Agitation
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients between the ages of 18 to 65 years, inclusive.
  2. Patients who have met criteria for schizophrenia and bipolar I disorder.
  3. Patients who are judged to be clinically acutely agitated with a total score of ≥ 14 on the 5 items comprising the PANSS-EC and at least one individual item score≥ 4 immediately before randomization.

Exclusion criteria

Exclusion Criteria:

  1. Patients with agitation caused by delirium, seizures, developmental delay, poisoning, etc., or withdrawal from drug abuse.
  2. Patients who have had previous suicidal behavior or currently at serious risk of suicide.
  3. Patients with glaucoma or at risk of angle-closure glaucoma.
  4. Patients who have brain diseases such as intracranial infection, brain trauma, cerebrovascular disease, basal ganglion disease, hypoxic encephalopathy, Parkinson's disease, Parkinson's syndrome, and dementia.
  5. Use of benzodiazepines, other hypnotics or short-acting antipsychotic drugs within 4 hours before randomization.
  6. Treatment with psychostimulants or reserpine within one week before randomization.
  7. Patients who received long-acting injections of typical or atypical antipsychotics within 2 weeks prior to randomization or within one injection interval.
  8. Treatment with clozapine within 4 weeks before screening.
  9. Patients with serious or unstable medical illnesses.
  10. Female patients who have a positive pregnancy test at screening or are breastfeeding.
  11. Patients who have participated in other clinical trials within 3 months before randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
318 participants (estimated)

Study arms

  • Experimental
    Olanzapine

    Drug: Olanzapine

  • Active comparator
    Haloperidol

    Drug: Haloperidol

Interventions

  • intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.

  • intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.

06

What researchers measure

Primary outcomes

  1. Change from baseline to 2 hours post-first IM injection on the PANSS-EC

    The PANSS-EC comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)

    Time frame: 2 hours

Secondary outcomes

  1. Percentage of Participants With 40% or Greater Percent Decrease in the PANSS-EC Total Score

    Time frame: 2 hours post-first IM injection

  2. Proportion of participants receiving one, two, or three doses of study drug during 24-hour intramuscular treatment period

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2023; primary completion for May 2024, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Apr 7, 2023
StartEst.
Mar 28, 2023
Primary completionEst.
May 7, 2024
CompletionEst.
Jul 2, 2024
Last update
Apr 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05803642
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Mar 28, 2023 (estimated)
Primary completion
May 7, 2024 (estimated)
Completion
Jul 2, 2024 (estimated)
Last update
Apr 7, 2023

Study contacts

Gang Wang, PhD
Contact
adwanggang@163.com
010-58303236

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion